<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Total plasma <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (tHcy) concentration is increased in elderly patients with <z:e sem="disease" ids="C0004936" disease_type="Mental or Behavioral Dysfunction" abbrv="">mental illness</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Also, patients with <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> have significantly higher plasma tHcy concentration compared with patients without <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="39015">Apolipoprotein</z:chebi> E (apoE) status is associated with <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and a major genetic risk factor is <z:hpo ids='HP_0000005'>inheritance</z:hpo> of the e4 allele </plain></SENT>
<SENT sid="3" pm="."><plain>In the present study, we investigated the association between plasma tHcy and apoE status </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: The relation between apoE status, plasma tHcy and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> was investigated in a cohort of consecutively enrolled elderly patients with <z:e sem="disease" ids="C0004936" disease_type="Mental or Behavioral Dysfunction" abbrv="">mental illness</z:e> (n=328) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Plasma tHcy concentrations were increased (p&lt;0.01) in carriers of APOE4 (13.6 micromol/L; 9.2-21.7 micromol/L) compared to non-carriers (12.4 micromol/L; 8.3-19.9 micromol/L) </plain></SENT>
<SENT sid="6" pm="."><plain>The proportion of patients with <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> was significantly (p&lt;0.001) increased among carriers (61%) compared to non-carriers (42%) </plain></SENT>
<SENT sid="7" pm="."><plain>An increased percentage (p&lt;0.001) of APOE4 carriers was observed in patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) with (71%) or without <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> (42%), and in patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) (54%) compared to a reference group (34%) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Since carriers of APOE4 showed an increased likelihood of <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e>, these patients need more intensive control of other modifiable vascular risk factors </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, the association between plasma tHcy and the presence of APOE4 might be attributed to an increased proportion of <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> in APOE4 carriers </plain></SENT>
</text></document>